Immune responses to influenza and pneumococcal conjugate vaccines in older adults compared to middle-aged adults and adults. - VITA

ational Institute of Health and the Environment0 个研究点目标入组 385 人开始时间: 2019年4月30日最近更新: 2023年10月3日

适应症

试验速览

暂无简介。

•Having had a previous pneumococcal vaccination (PCV or the 23-valent pneumococcal polysaccharide vaccine (PPV23)).
•Known or suspected allergy to any of the vaccine components or having experienced a previous severe adverse reaction to any vaccine.
•Receipt of any high-dose (= 20 mg of prednisone daily or equivalent) daily corticosteroids (local incl. inhaled steroids are acceptable) within 2 weeks of study entry.
•Repeated use of any high dose of corticosteroids (a dose of > 30 mg of prednisone or equivalent per day for multiple days) in the recent past.
•Receipt of an organ- or bone marrow transplant
•Have a (functional) asplenie.
•Receipt of chemotherapy in the last 3 years.
•Receipt of blood products or immunoglobulin, within three months of study entry.
•Known or suspected coagulation disorder that in the opinion of the investigator would contraindicate against receiving an intramuscular injection or undergo frequent blood sampling.
•Known anemia, measured as Hb < ( 8,5 mmol/l for men and 7,5 mmol/l for woman; NHG standard Anemia)
•Known to be positive for human immunodeficiency virus (HIV), and/or hepatitis C virus (HCV) and/or hepatitis B virus (HBV).
•Exclusion criteria COVID-19 vaccination study
•Treatment with COVID-19 monoclonal antibodies less that 3 months before COVID-19 vaccination.
•Known pregnancy at the moment of COVID-19 vaccination.

发起方

ational Institute of Health and the Environment